99mTc-HL91: Effects of low flow and hypoxia on a new ischemia-avid myocardial imaging agent

Circulation

Volumn 95, Issue 7, 1997, Pages 1892-1899

  Okada, Robert D ^d   Johnson III, Gerald ^c   Nguyen, Kiem N ^d   Edwards, Barbara ^a,b   Archer, Colin M ^a,b   Kelly, James D ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b GENERAL ELECTRIC COMPANY   (United States)

^c William K Warren Med Res Cent   (United States)

^d NONE

Author keywords

hypoxia; ischemia; myocardium; radioisotopes

Indexed keywords

CREATINE KINASE; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; UPENAZIME; UPENAZIME TC 99M; CONTRAST MEDIUM; DIAGNOSTIC AGENT; ISOENZYME; OXIME; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 4,9 DIAZA 3,3,10,10 TETRAMETHYLDODECAN 2,11 DIONE DIOXIME; TECHNETIUM TC 99M 4,9-DIAZA-3,3,10,10-TETRAMETHYLDODECAN-2,11-DIONE DIOXIME;

ANIMAL TISSUE; ARTICLE; CLEARANCE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ASSAY; FLOW RATE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEMODYNAMICS; HYPOXIA; IMAGING; ISOLATED HEART; NONHUMAN; OXYGEN TISSUE LEVEL; PRIORITY JOURNAL; RADIOACTIVITY; RAT; ANIMAL; BLOOD; CELL HYPOXIA; COMPARATIVE STUDY; CORONARY ARTERY BLOOD FLOW; HEART; HEART MUSCLE; METABOLISM; SCINTILLATION CAMERA; SCINTISCANNING;

ANIMALS; CELL HYPOXIA; CONTRAST MEDIA; CORONARY CIRCULATION; CREATINE KINASE; GAMMA CAMERAS; HEART; ISOENZYMES; MYOCARDIAL ISCHEMIA; MYOCARDIUM; ORGANOTECHNETIUM COMPOUNDS; OXIMES; RATS;

EID: 0030615304     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.7.1892     Document Type: Article

References (30)

1. Chapman JD. Hypoxic sensitizer: implications for radiation therapy. N Engl J Med. 1979;301:1429-1432.
2. Chapman JD, Franco AJ, Sharplin J. A marker for hypoxic cells in tumors with potential clinical applicability. Br J Cancer. 1981;43: 546-550.
3. 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int J Radiat Oncol Biol Phys. 1986;12:1263-1267.
4. International Conference on Dose, Time, and Fractionation. Prediction of response in radiation therapy. In: Paliwal BR, et al, eds. Symposium Proceedings of the American Association of Physicists in Medicine. New York, NY: American Institute of Physics; 1989;2: 1-757.
5. Koh W-J, Rasey JS, Evans ML. Imaging of hypoxia in human tumors with [F-18] fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
6. Groshar D, McEwan AJB, Parliament MB, Urtasun RC, Golberg LE, Hoskinson M, Mercer JR, Mannan RH, Wiebe LI, Chapman JD. Imaging tumor hypoxia and tumor perfusion. J Nucl Med. 1993;34:885-888.
7. Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD, Wiebe LI. Radioiodinated 1-(5-iodo-5-deoxy-β-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J Nucl Med. 1991;32:1764-1770.
8. 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer. 1992;65: 90-95.
9. Martin GV, Caldwell JH, Graham MM, Grierson JR, Kroll K, Cowan MJ, Lewellen TK, Rasey JS, Casciari JJ, Krohn KA. Non-invasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med. 1992;33:2202-2208.
10. Shelton ME, Dence CS, Hwang D-R, Herrero P, Welch MJ, Bergmann SR. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. J Am Coll Cardiol. 1990;16: 477-485.
11. Shelton ME, Dence C, Hwang D-R, Welch MJ. Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. J Nucl Med. 1989;30:351-358.
12. 3H] fluoromisonidazole in ischemic myocardium. J Nucl Med. 1989;30: 194-201.
13. Martin GV, Cerqueira M, Caldwell JH, Rasey JS, Embree L, Krohn KA. Fluoromisonidazole: a metabolic marker of myocyte hypoxia. Circ Res. 1990;67:240-244.
14. Martin GV, Biskupiak JE, Caldwell JH, Rasey JS, Krohn KA. Characterization of iodovinylmisonidazole as a marker for myocardial hypoxia. J Nucl Med. 1993;34:918-924.
15. Rumsey WL, Cyr JE, Raju N. A novel [99 m]technetium-labeled nitroheterocycle capable of identification of hypoxia in heart. Biochem Biophys Res Commun. 1993;193:1239-1246.
16. Kusuoka H, Hashimoto K, Fukuchi K, Nishimura T. Kinetics of a putative hypoxic tissue marker, technetium-99 m-nitroimidazole (BMS181321), in normoxic, hypoxic, ischemic and stunned myocardium. J Nucl Med. 1994;35:1371-1376.
17. Rumsey WL, Patel B, Linder K. Effects of graded hypoxia in retention of technetium-99 m-nitroheterocycle in perfused rat hearts. J Nucl Med. 1995;36:632-636.
18. Stone CK, Mulnix T, Nickles RJ, Renstrom B, Nellis SH, Liedtke J, Nunn AD, Kuczynski BL, Rumsey WL. Myocardial kinetics of a putative hypoxic tissue marker, 99 m-Tc-labeled nitroimidazole (BMS181321), after regional ischemia and reperfusion. Circulation. 1995;92:1246-1253.
19. Shi CQ, Sinusas AJ, Dione DP, Singer MJ, Young LH, Heller EN, Rinker BD, Wackers FJT, Zaret BL. Technetium-99 m nitroimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia. J Nucl Med. 1995;36:1078-1086.
20. Ng CK, Sinusas AJ, Zaret B, Souter R. Kinetic analysis of technetium-99 m-labeled nitroimidazole (BMS181321) as a tracer of myocardial hypoxia. Circulation. 1995;92:1261-1268.
21. Archer CM, Edwards B, Kelly JD, King AC, Burke JF, Riley ALM. Technetium labelled agents for imaging tissue hypoxia in vivo. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and Rhenium in Chemistry and Nuclear Medicine. Padova, Italy: SGE Ditoriali Publishers; 1995:535-539.
22. Okada RD, Nguyen KN, Lauinger M, Allton IL, Johnson G III. Technetium 99 m-Q12 kinetics in perfused rat myocardium: effects of hypoxia and low flow. Am Heart J. 1996;132:108-115.
23. Vanderkooi JM, Erecinska M, Silver IA. Oxygen in mammalian tissue: methods of measurement and affinities of various reactions. Am J Physiol. 1991;260:C1131-C1150.
24. Franco AJ. Misonidazole and other hypoxia markers: metabolism and implications. Int J Radiat Oncol Biol Phys. 1986;12:1195-1202.
25. Whitmore GF, Varghese AJ. The biological properties of reduced nitroheterocyclics and possible underlying biochemical mechanisms. Biochem Pharmacol. 1986;35:97-103.
26. Rasey JS, Krohn KA, Grunbaum Z, Conroy PJ, Bauer K, Sutherland RM. Further characterization of 4-bromomisonidazole as a potential detector of hypoxic cells. Radiat Res. 1985;102:76-85.
27. Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, Krohn KA. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radial Res. 1987;111: 292-297.
28. Okada RD, Nguyen KN, Strauss HW, Johnson G III. Effects of low flow on myocardial retention of technetium-99 m BMS181321. Eur J Nucl Med. 1996;23:443-447.
29. Rumsey WL, Patel B, Kuczynski B, Hood C, Linder E, Nunn A, Strauss HW. Comparison of two novel technetium agents for imaging ischemic myocardium. Circulation. 1995;92:181. Abstract.
30. Stone CK, Mulnix T, Nickles RJ, Carlson KJ, Renstrom B, Nellis SH, Liedke AJ, Nunn AD. Comparison of the myocardial and hepatic uptake of two technetium-labeled nitroimidazoles after regional ischemia and reperfusion using a dual isotope technique. J Nucl Med. 1995;36:138. Abstract.